BioXcel Therapeutics (BTAI) Misses Q3 EPS by 17c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($1.49), $0.17 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $140 thousand versus the consensus estimate of $1.12 million.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook